The Distribution of Pelvic Nodal Metastases in Prostate Cancer Reveals Potential to Advance and Personalize Pelvic Radiotherapy

BackgroundTraditional clinical target volume (CTV) definition for pelvic radiotherapy in prostate cancer consists of large volumes being treated with homogeneous doses without fully utilizing information on the probability of microscopic involvement to guide target volume design and prescription dos...

Full description

Bibliographic Details
Main Authors: Irina Filimonova, Daniela Schmidt, Sina Mansoorian, Thomas Weissmann, Hadi Siavooshhaghighi, Alexander Cavallaro, Torsten Kuwert, Christoph Bert, Benjamin Frey, Luitpold Valentin Distel, Sebastian Lettmaier, Rainer Fietkau, Florian Putz
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-01-01
Series:Frontiers in Oncology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2020.590722/full
id doaj-12ad4779d1f3486294fda38e55a70cc6
record_format Article
collection DOAJ
language English
format Article
sources DOAJ
author Irina Filimonova
Daniela Schmidt
Sina Mansoorian
Thomas Weissmann
Hadi Siavooshhaghighi
Alexander Cavallaro
Torsten Kuwert
Christoph Bert
Benjamin Frey
Luitpold Valentin Distel
Sebastian Lettmaier
Rainer Fietkau
Florian Putz
spellingShingle Irina Filimonova
Daniela Schmidt
Sina Mansoorian
Thomas Weissmann
Hadi Siavooshhaghighi
Alexander Cavallaro
Torsten Kuwert
Christoph Bert
Benjamin Frey
Luitpold Valentin Distel
Sebastian Lettmaier
Rainer Fietkau
Florian Putz
The Distribution of Pelvic Nodal Metastases in Prostate Cancer Reveals Potential to Advance and Personalize Pelvic Radiotherapy
Frontiers in Oncology
prostate cancer
lymph node metastases
mapping
patterns of recurrence
pelvic radiotherapy
author_facet Irina Filimonova
Daniela Schmidt
Sina Mansoorian
Thomas Weissmann
Hadi Siavooshhaghighi
Alexander Cavallaro
Torsten Kuwert
Christoph Bert
Benjamin Frey
Luitpold Valentin Distel
Sebastian Lettmaier
Rainer Fietkau
Florian Putz
author_sort Irina Filimonova
title The Distribution of Pelvic Nodal Metastases in Prostate Cancer Reveals Potential to Advance and Personalize Pelvic Radiotherapy
title_short The Distribution of Pelvic Nodal Metastases in Prostate Cancer Reveals Potential to Advance and Personalize Pelvic Radiotherapy
title_full The Distribution of Pelvic Nodal Metastases in Prostate Cancer Reveals Potential to Advance and Personalize Pelvic Radiotherapy
title_fullStr The Distribution of Pelvic Nodal Metastases in Prostate Cancer Reveals Potential to Advance and Personalize Pelvic Radiotherapy
title_full_unstemmed The Distribution of Pelvic Nodal Metastases in Prostate Cancer Reveals Potential to Advance and Personalize Pelvic Radiotherapy
title_sort distribution of pelvic nodal metastases in prostate cancer reveals potential to advance and personalize pelvic radiotherapy
publisher Frontiers Media S.A.
series Frontiers in Oncology
issn 2234-943X
publishDate 2021-01-01
description BackgroundTraditional clinical target volume (CTV) definition for pelvic radiotherapy in prostate cancer consists of large volumes being treated with homogeneous doses without fully utilizing information on the probability of microscopic involvement to guide target volume design and prescription dose distribution.MethodsWe analyzed patterns of nodal involvement in 75 patients that received RT for pelvic and paraaortic lymph node metastases (LNs) from prostate cancer in regard to the new NRG-CTV recommendation. Non-rigid registration-based LN mapping and weighted three-dimensional kernel density estimation were used to visualize the average probability distribution for nodal metastases. As independent approach, the mean relative proportion of LNs observed for each level was determined manually and NRG and non-NRG levels were evaluated for frequency of involvement. Computer-automated distance measurements were used to compare LN distances in individual patients to the spatial proximity of nodal metastases at a cohort level.Results34.7% of patients had pelvic LNs outside NRG-consensus, of which perirectal was most common (25.3% of all patients) followed by left common iliac nodes near the left psoas major (6.7%). A substantial portion of patients (13.3%) had nodes at the posterior edge of the NRG obturator level. Observer-independent mapping consistently visualized high-probability hotspots outside NRG-consensus in the perirectal and left common iliac regions. Affected nodes in individual patients occurred in highly significantly closer proximity than at cohort-level (mean distance, 6.6 cm vs. 8.7 cm, p < 0.001).ConclusionsBased on this analysis, the common iliac level should extend to the left psoas major and obturator levels should extend posteriorly 5 mm beyond the obturator internus. Incomplete coverage by the NRG-consensus was mostly because of perirectal involvement. We introduce three-dimensional kernel density estimation after non-rigid registration-based mapping for the analysis of recurrence data in radiotherapy. This technique provides an estimate of the underlying probability distribution of nodal involvement and may help in addressing institution- or subgroup-specific differences. Nodal metastases in individual patients occurred in highly significantly closer proximity than at a cohort-level, which supports that personalized target volumes could be reduced in size compared to a “one-size-fits-all” approach and is an important basis for further investigation into individualized field designs.
topic prostate cancer
lymph node metastases
mapping
patterns of recurrence
pelvic radiotherapy
url https://www.frontiersin.org/articles/10.3389/fonc.2020.590722/full
work_keys_str_mv AT irinafilimonova thedistributionofpelvicnodalmetastasesinprostatecancerrevealspotentialtoadvanceandpersonalizepelvicradiotherapy
AT danielaschmidt thedistributionofpelvicnodalmetastasesinprostatecancerrevealspotentialtoadvanceandpersonalizepelvicradiotherapy
AT sinamansoorian thedistributionofpelvicnodalmetastasesinprostatecancerrevealspotentialtoadvanceandpersonalizepelvicradiotherapy
AT thomasweissmann thedistributionofpelvicnodalmetastasesinprostatecancerrevealspotentialtoadvanceandpersonalizepelvicradiotherapy
AT hadisiavooshhaghighi thedistributionofpelvicnodalmetastasesinprostatecancerrevealspotentialtoadvanceandpersonalizepelvicradiotherapy
AT alexandercavallaro thedistributionofpelvicnodalmetastasesinprostatecancerrevealspotentialtoadvanceandpersonalizepelvicradiotherapy
AT torstenkuwert thedistributionofpelvicnodalmetastasesinprostatecancerrevealspotentialtoadvanceandpersonalizepelvicradiotherapy
AT christophbert thedistributionofpelvicnodalmetastasesinprostatecancerrevealspotentialtoadvanceandpersonalizepelvicradiotherapy
AT benjaminfrey thedistributionofpelvicnodalmetastasesinprostatecancerrevealspotentialtoadvanceandpersonalizepelvicradiotherapy
AT luitpoldvalentindistel thedistributionofpelvicnodalmetastasesinprostatecancerrevealspotentialtoadvanceandpersonalizepelvicradiotherapy
AT sebastianlettmaier thedistributionofpelvicnodalmetastasesinprostatecancerrevealspotentialtoadvanceandpersonalizepelvicradiotherapy
AT rainerfietkau thedistributionofpelvicnodalmetastasesinprostatecancerrevealspotentialtoadvanceandpersonalizepelvicradiotherapy
AT florianputz thedistributionofpelvicnodalmetastasesinprostatecancerrevealspotentialtoadvanceandpersonalizepelvicradiotherapy
AT irinafilimonova distributionofpelvicnodalmetastasesinprostatecancerrevealspotentialtoadvanceandpersonalizepelvicradiotherapy
AT danielaschmidt distributionofpelvicnodalmetastasesinprostatecancerrevealspotentialtoadvanceandpersonalizepelvicradiotherapy
AT sinamansoorian distributionofpelvicnodalmetastasesinprostatecancerrevealspotentialtoadvanceandpersonalizepelvicradiotherapy
AT thomasweissmann distributionofpelvicnodalmetastasesinprostatecancerrevealspotentialtoadvanceandpersonalizepelvicradiotherapy
AT hadisiavooshhaghighi distributionofpelvicnodalmetastasesinprostatecancerrevealspotentialtoadvanceandpersonalizepelvicradiotherapy
AT alexandercavallaro distributionofpelvicnodalmetastasesinprostatecancerrevealspotentialtoadvanceandpersonalizepelvicradiotherapy
AT torstenkuwert distributionofpelvicnodalmetastasesinprostatecancerrevealspotentialtoadvanceandpersonalizepelvicradiotherapy
AT christophbert distributionofpelvicnodalmetastasesinprostatecancerrevealspotentialtoadvanceandpersonalizepelvicradiotherapy
AT benjaminfrey distributionofpelvicnodalmetastasesinprostatecancerrevealspotentialtoadvanceandpersonalizepelvicradiotherapy
AT luitpoldvalentindistel distributionofpelvicnodalmetastasesinprostatecancerrevealspotentialtoadvanceandpersonalizepelvicradiotherapy
AT sebastianlettmaier distributionofpelvicnodalmetastasesinprostatecancerrevealspotentialtoadvanceandpersonalizepelvicradiotherapy
AT rainerfietkau distributionofpelvicnodalmetastasesinprostatecancerrevealspotentialtoadvanceandpersonalizepelvicradiotherapy
AT florianputz distributionofpelvicnodalmetastasesinprostatecancerrevealspotentialtoadvanceandpersonalizepelvicradiotherapy
_version_ 1724344611160195072
spelling doaj-12ad4779d1f3486294fda38e55a70cc62021-01-08T06:14:19ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2021-01-011010.3389/fonc.2020.590722590722The Distribution of Pelvic Nodal Metastases in Prostate Cancer Reveals Potential to Advance and Personalize Pelvic RadiotherapyIrina Filimonova0Daniela Schmidt1Sina Mansoorian2Thomas Weissmann3Hadi Siavooshhaghighi4Alexander Cavallaro5Torsten Kuwert6Christoph Bert7Benjamin Frey8Luitpold Valentin Distel9Sebastian Lettmaier10Rainer Fietkau11Florian Putz12Department of Radiation Oncology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, GermanyDepartment of Nuclear Medicine, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, GermanyDepartment of Radiation Oncology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, GermanyDepartment of Radiation Oncology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, GermanyDepartment of Radiation Oncology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, GermanyInstitute of Radiology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, GermanyDepartment of Nuclear Medicine, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, GermanyDepartment of Radiation Oncology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, GermanyDepartment of Radiation Oncology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, GermanyDepartment of Radiation Oncology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, GermanyDepartment of Radiation Oncology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, GermanyDepartment of Radiation Oncology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, GermanyDepartment of Radiation Oncology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, GermanyBackgroundTraditional clinical target volume (CTV) definition for pelvic radiotherapy in prostate cancer consists of large volumes being treated with homogeneous doses without fully utilizing information on the probability of microscopic involvement to guide target volume design and prescription dose distribution.MethodsWe analyzed patterns of nodal involvement in 75 patients that received RT for pelvic and paraaortic lymph node metastases (LNs) from prostate cancer in regard to the new NRG-CTV recommendation. Non-rigid registration-based LN mapping and weighted three-dimensional kernel density estimation were used to visualize the average probability distribution for nodal metastases. As independent approach, the mean relative proportion of LNs observed for each level was determined manually and NRG and non-NRG levels were evaluated for frequency of involvement. Computer-automated distance measurements were used to compare LN distances in individual patients to the spatial proximity of nodal metastases at a cohort level.Results34.7% of patients had pelvic LNs outside NRG-consensus, of which perirectal was most common (25.3% of all patients) followed by left common iliac nodes near the left psoas major (6.7%). A substantial portion of patients (13.3%) had nodes at the posterior edge of the NRG obturator level. Observer-independent mapping consistently visualized high-probability hotspots outside NRG-consensus in the perirectal and left common iliac regions. Affected nodes in individual patients occurred in highly significantly closer proximity than at cohort-level (mean distance, 6.6 cm vs. 8.7 cm, p < 0.001).ConclusionsBased on this analysis, the common iliac level should extend to the left psoas major and obturator levels should extend posteriorly 5 mm beyond the obturator internus. Incomplete coverage by the NRG-consensus was mostly because of perirectal involvement. We introduce three-dimensional kernel density estimation after non-rigid registration-based mapping for the analysis of recurrence data in radiotherapy. This technique provides an estimate of the underlying probability distribution of nodal involvement and may help in addressing institution- or subgroup-specific differences. Nodal metastases in individual patients occurred in highly significantly closer proximity than at a cohort-level, which supports that personalized target volumes could be reduced in size compared to a “one-size-fits-all” approach and is an important basis for further investigation into individualized field designs.https://www.frontiersin.org/articles/10.3389/fonc.2020.590722/fullprostate cancerlymph node metastasesmappingpatterns of recurrencepelvic radiotherapy